Title: An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors.
Journal: Expert opinion on pharmacotherapy 20130701
Title: Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties.
Journal: Therapeutic advances in urology 20130201
Title: Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus.
Journal: Mayo Clinic proceedings 20120901
Title: Re: Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial.
Journal: The Journal of urology 20120901
Title: Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction.
Journal: The Journal of urology 20120801
Title: Efficacy and satisfaction rates of oral PDE5is in the treatment of erectile dysfunction secondary to spinal cord injury: a review of literature.
Journal: The journal of spinal cord medicine 20120701
Title: FDA approves new ED remedy.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120601
Title: A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction.
Journal: The journal of sexual medicine 20120401
Title: Avanafil for the treatment of erectile dysfunction.
Journal: Drugs of today (Barcelona, Spain : 1998) 20120101
Title: Avanafil for treatment of erectile dysfunction: review of its potential.
Journal: Vascular health and risk management 20120101
Title: cGMP Signaling, Phosphodiesterases and Major Depressive Disorder.
Journal: Current neuropharmacology 20111201
Title: Novel phosphodiesterase type 5 modulators: a patent survey (2008 - 2010).
Journal: Expert opinion on therapeutic patents 20111001
Title: Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction.
Journal: British journal of clinical pharmacology 20110801
Title: Future prospects in the treatment of erectile dysfunction: focus on avanafil.
Journal: Drug design, development and therapy 20110101
Title: Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction.
Journal: Expert opinion on investigational drugs 20101101
Title: Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers.
Journal: Clinical therapeutics 20100601
Title: Diagnosis and treatment of erectile dysfunction--a practical update.
Journal: Journal of medicine and life 20091115
Title: Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.
Journal: Psychopharmacology 20090101
Title: Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress.
Journal: Expert opinion on investigational drugs 20080601
Title: Looking to the future for erectile dysfunction therapies.
Journal: Drugs 20080101
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20061201
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20061001
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20060901
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20040101
Title: Huyut Z, et, al. Effects of the Phosphodiesterase-5 (PDE-5) Inhibitors, Avanafil and Zaprinast, on Bone Remodeling and Oxidative Damage in a Rat Model of Glucocorticoid-Induced Osteoporosis. Med Sci Monit Basic Res. 2018 Mar 13;24:47-58.
Title: Yilmaz D, et, al. The effect of intracavernosal avanafil, a newer phosphodiesterase-5 inhibitor, on neonatal type 2 diabetic rats with erectile dysfunction. Urology. 2014 Feb;83(2):508.e7-12.
Title: Kotera J, et, al. Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction. J Urol. 2012 Aug;188(2):668-74.
